206 related articles for article (PubMed ID: 22507556)
1. Study of CCN3 (NOV) and DDR1 in normal melanocytes and vitiligo skin.
Ricard AS; Pain C; Daubos A; Ezzedine K; Lamrissi-Garcia I; Bibeyran A; Guyonnet-Dupérat V; Taieb A; Cario-André M
Exp Dermatol; 2012 Jun; 21(6):411-6. PubMed ID: 22507556
[TBL] [Abstract][Full Text] [Related]
2. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1.
Fukunaga-Kalabis M; Martinez G; Liu ZJ; Kalabis J; Mrass P; Weninger W; Firth SM; Planque N; Perbal B; Herlyn M
J Cell Biol; 2006 Nov; 175(4):563-9. PubMed ID: 17101694
[TBL] [Abstract][Full Text] [Related]
3. Discoidin domain receptor-1 as a player in impairment of melanocytes adhesion process in vitiligo.
Elgarhy LH; Abdullatif A; Abdelazim R; El-Desouky KI
G Ital Dermatol Venereol; 2016 Oct; 151(5):473-9. PubMed ID: 26091274
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of the E-cadherin gene CDH1 is associated with susceptibility to vitiligo.
Tarlé RG; Silva de Castro CC; do Nascimento LM; Mira MT
Exp Dermatol; 2015 Apr; 24(4):300-2. PubMed ID: 25613741
[TBL] [Abstract][Full Text] [Related]
5. Reduced immunohistochemical expression of CCN3 in vitiligo.
Faria AR; Jung JE; Silva de Catro CC; de Noronha L
Indian J Dermatol Venereol Leprol; 2018; 84(5):558-562. PubMed ID: 29998862
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants of the DDR1 gene are associated with vitiligo in two independent Brazilian population samples.
Silva de Castro CC; do Nascimento LM; Walker G; Werneck RI; Nogoceke E; Mira MT
J Invest Dermatol; 2010 Jul; 130(7):1813-8. PubMed ID: 20182441
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of CCN3 (NOV) expression in the epidermis of systemic sclerosis patients with pigmentary changes.
Henrot P; Pain C; Taïeb A; Truchetet ME; Cario M
Pigment Cell Melanoma Res; 2020 Nov; 33(6):895-898. PubMed ID: 32633087
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo.
van den Wijngaard RM; Asghar SS; Pijnenborg AC; Tigges AJ; Westerhof W; Das PK
Br J Dermatol; 2002 Jan; 146(1):80-7. PubMed ID: 11841370
[TBL] [Abstract][Full Text] [Related]
9. Low-energy helium-neon laser induces melanocyte proliferation via interaction with type IV collagen: visible light as a therapeutic option for vitiligo.
Lan CC; Wu CS; Chiou MH; Chiang TY; Yu HS
Br J Dermatol; 2009 Aug; 161(2):273-80. PubMed ID: 19438447
[TBL] [Abstract][Full Text] [Related]
10. The melanocytorrhagic hypothesis of vitiligo tested on pigmented, stressed, reconstructed epidermis.
Cario-André M; Pain C; Gauthier Y; Taïeb A
Pigment Cell Res; 2007 Oct; 20(5):385-93. PubMed ID: 17850512
[TBL] [Abstract][Full Text] [Related]
11. Aberrant ETS-1 signalling impedes the expression of cell adhesion molecules and matrix metalloproteinases in non-segmental vitiligo.
Srivastava N; Bishnoi A; Mehta S; Rani S; Kumar R; Bhardwaj S; Sendhil Kumaran M; Keshavamurthy V; Gupta S; Parsad D
Exp Dermatol; 2020 Jun; 29(6):539-547. PubMed ID: 32350934
[TBL] [Abstract][Full Text] [Related]
12. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions.
Moretti S; Spallanzani A; Amato L; Hautmann G; Gallerani I; Fabiani M; Fabbri P
Pigment Cell Res; 2002 Apr; 15(2):87-92. PubMed ID: 11936274
[TBL] [Abstract][Full Text] [Related]
13. Immunolocalization of tenascin-C in vitiligo.
Abdou AG; Maraee AH; Shoeib MA; Elbana R
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):501-11. PubMed ID: 22495383
[TBL] [Abstract][Full Text] [Related]
14. CDH1 and DDR1 common variants confer risk to vitiligo and autoimmune comorbidities.
Almasi-Nasrabadi M; Amoli MM; Robati RM; Rajabi F; Ghalamkarpour F; Gauthier Y
Gene; 2019 Jun; 700():17-22. PubMed ID: 30890477
[TBL] [Abstract][Full Text] [Related]
15. Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion.
Le Poole IC; van den Wijngaard RM; Westerhof W; Das PK
Br J Dermatol; 1997 Aug; 137(2):171-8. PubMed ID: 9292062
[TBL] [Abstract][Full Text] [Related]
16. Epidermal hydrogen peroxide is not increased in lesional and non-lesional skin of vitiligo.
Zailaie MZ
Arch Dermatol Res; 2017 Jan; 309(1):31-42. PubMed ID: 27783153
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of CCN3 expression as a potential mechanism for melanoma progression.
Fukunaga-Kalabis M; Martinez G; Telson SM; Liu ZJ; Balint K; Juhasz I; Elder DE; Perbal B; Herlyn M
Oncogene; 2008 Apr; 27(18):2552-60. PubMed ID: 17968313
[TBL] [Abstract][Full Text] [Related]
18. Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo.
Wagner RY; Luciani F; Cario-André M; Rubod A; Petit V; Benzekri L; Ezzedine K; Lepreux S; Steingrimsson E; Taieb A; Gauthier Y; Larue L; Delmas V
J Invest Dermatol; 2015 Jul; 135(7):1810-1819. PubMed ID: 25634357
[TBL] [Abstract][Full Text] [Related]
19. Expression of discoidin domain receptor 1 and E-cadherin in epidermis affects melanocyte behavior in rhododendrol-induced leukoderma mouse model.
Abe Y; Hozumi Y; Okamura K; Suzuki T
J Dermatol; 2020 Nov; 47(11):1330-1334. PubMed ID: 32770866
[TBL] [Abstract][Full Text] [Related]
20. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.
Boukhedouni N; Martins C; Darrigade AS; Drullion C; Rambert J; Barrault C; Garnier J; Jacquemin C; Thiolat D; Lucchese F; Morel F; Ezzedine K; Taieb A; Bernard FX; Seneschal J; Boniface K
JCI Insight; 2020 Jun; 5(11):. PubMed ID: 32369451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
